Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626249 · ClinicalTrials.gov registry record · Phase 1
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00626249 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 36 participants.
The verdict
NCT00626249, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
24 diabetics with mild \& moderate renal disease and 12 diabetics without renal disease. One screening, one dosing \& one follow-up visit with Technosphere® Inhalation Powder given at Visit 2 via MedTone® Inhaler and PK testing at 26 designated time points
Interventions
- DRUG Technosphere Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626249
The ClinicalTrials.gov registry entry for NCT00626249 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Technosphere Inhalation Powder is the first listed.
NCT00626249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626249 about?
NCT00626249 is a clinical study titled "Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function". 24 diabetics with mild \& moderate renal disease and 12 diabetics without renal disease. One screening, one dosing \& one follow-up visit with Technosphere® Inhalation Powder given at Visit 2 via MedTone® Inhaler and PK testing at 26 designated time points
What is the current status of trial NCT00626249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00626249?
The interventions under investigation include: Technosphere Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT00626249?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.